Pharmacogenomics · 2012 · 30 citations · 29 references
Life SciencesGeneticsImmunologyImmunogeneticsMedical GeneticsRheumatologyAnkylosing SpondylitisCytokine Gene PolymorphismImmune-mediated Inflammatory DiseasesAnti-inflammatory Cytokine VariantsGenetic PolymorphismsInflammatory Gene Polymorphism AnalysisInflammatory Mediator PolymorphismsTherapeutic Response MonitoringTherapeutic Response PredictionTumor Necrosis Factor Alpha VariantsTumor Necrosis Factor Gene Variants
AIM: To evaluate whether polymorphisms at -857, -1031, -308 and -238 positions of the TNF-α gene influence response to TNF-α-blocker therapy in Chinese Han patients with ankylosing spondylitis. PATIENTS & METHODS: A total of 106 patients with ankylosing spondylitis were recruited and genotyped for -857, -1031, -308 and -238 TNF-α gene polymorphisms. In total, 32 received infliximab and 74 received a recombinant human TNF-α receptor II-IgG Fc fusion protein (rhTNFR-Fc). At the end of 12 weeks, patients were assessed using the Assessment of SpondyloArthritis International Society (ASAS) 20, 40, 50 and 70 criteria. RESULTS: Polymorphisms at -308 and -238 did not affect therapeutic response. The -857 C/C genotype (p = 0.0021) responded better to therapy. The -1031 T/T genotype (p = 0.0004) showed better outcome. CONCLUSION: In Chinese Han ankylosing spondylitis patients, polymorphisms at the -308 and -238 positions of the TNF-α gene are unable to predict TNF-α-blocker response; however, -857 C/C and -1031 T/T genotypes have the ability to predict good response.
29
Michael Seitz, U. Wirthmüller, Burkhard Möller et al. · Lara D. Veeken · 2006 · 196 citations · Full text